183 related articles for article (PubMed ID: 23266353)
41. Aberrant methylation of the VIM promoter in uterine cervical squamous cell carcinoma.
Lee MK; Jeong EM; Kim JH; Rho SB; Lee EJ
Oncology; 2014; 86(5-6):359-68. PubMed ID: 24942637
[TBL] [Abstract][Full Text] [Related]
42. TP53 mutants and non-HPV16/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer.
Kuno I; Takayanagi D; Asami Y; Murakami N; Matsuda M; Shimada Y; Hirose S; Kato MK; Komatsu M; Hamamoto R; Okuma K; Kohno T; Itami J; Yoshida H; Shiraishi K; Kato T
Sci Rep; 2021 Sep; 11(1):19261. PubMed ID: 34584128
[TBL] [Abstract][Full Text] [Related]
43. Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women.
Chung TKH; Cheung TH; Yim SF; Yu MY; Chiu RWK; Lo KWK; Lee IPC; Wong RRY; Lau KKM; Wang VW; Worley MJ; Elias KM; Fiascone SJ; Smith DI; Berkowitz RS; Wong YF
Gynecol Oncol; 2017 Aug; 146(2):334-339. PubMed ID: 28587748
[TBL] [Abstract][Full Text] [Related]
44. AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma.
Saglam O; Husain S; Toruner G
Int J Gynecol Pathol; 2013 Sep; 32(5):493-500. PubMed ID: 23896716
[TBL] [Abstract][Full Text] [Related]
45. Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing.
Schildgen V; Lüsebrink J; Appel JD; Wübben C; Engel-Riedel W; Ludwig C; Stoelben E; Schildgen O; Brockmann M
Diagn Mol Pathol; 2013 Mar; 22(1):22-7. PubMed ID: 23370426
[TBL] [Abstract][Full Text] [Related]
46. Lymphopenia and its association with survival in patients with locally advanced cervical cancer.
Wu ES; Oduyebo T; Cobb LP; Cholakian D; Kong X; Fader AN; Levinson KL; Tanner EJ; Stone RL; Piotrowski A; Grossman S; Roche KL
Gynecol Oncol; 2016 Jan; 140(1):76-82. PubMed ID: 26571200
[TBL] [Abstract][Full Text] [Related]
47. PIK3CA Mutations in Resected Small Cell Lung Cancer.
Han N; Cheng QY; Chen B; Cai JF; Wang XJ; Lou CJ; Qin J; Ye WW; Lei L; Lu HY
Adv Clin Exp Med; 2016; 25(3):397-402. PubMed ID: 27629725
[TBL] [Abstract][Full Text] [Related]
48. TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
Tornesello ML; Annunziata C; Buonaguro L; Losito S; Greggi S; Buonaguro FM
J Transl Med; 2014 Sep; 12():255. PubMed ID: 25220666
[TBL] [Abstract][Full Text] [Related]
49. Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer.
Ito C; Nishizuka SS; Ishida K; Uesugi N; Sugai T; Tamura G; Koeda K; Sasaki A
J Surg Res; 2017 May; 212():195-204. PubMed ID: 28550907
[TBL] [Abstract][Full Text] [Related]
50. Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome.
Spaans VM; Trietsch MD; Peters AA; Osse M; Ter Haar N; Fleuren GJ; Jordanova ES
PLoS One; 2015; 10(7):e0133670. PubMed ID: 26197069
[TBL] [Abstract][Full Text] [Related]
51. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Zammataro L; Lopez S; Bellone S; Pettinella F; Bonazzoli E; Perrone E; Zhao S; Menderes G; Altwerger G; Han C; Zeybek B; Bianchi A; Manzano A; Manara P; Cocco E; Buza N; Hui P; Wong S; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Angioli R; Raspagliesi F; Scambia G; Choi J; Dong W; Bilguvar K; Alexandrov LB; Silasi DA; Huang GS; Ratner E; Azodi M; Schwartz PE; Pirazzoli V; Stiegler AL; Boggon TJ; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22730-22736. PubMed ID: 31624127
[TBL] [Abstract][Full Text] [Related]
52. Genetic variations in the PI3K/AKT pathway predict platinum-based neoadjuvant chemotherapeutic sensitivity in squamous cervical cancer.
Guo L; Wu H; Zhu J; Zhang C; Ma J; Lan J; Xie X
Life Sci; 2015 Dec; 143():217-24. PubMed ID: 26585822
[TBL] [Abstract][Full Text] [Related]
53. The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
Spaans VM; Nyoman Bayu Mahendra I; Purwoto G; Trietsch MD; Osse M; Ter Haar N; Peters AAW; Fleuren GJ; Jordanova ES
Gynecol Oncol; 2018 Jan; 148(1):189-196. PubMed ID: 29113722
[TBL] [Abstract][Full Text] [Related]
54. PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer.
Xiang L; Jiang W; Li J; Shen X; Yang W; Yang G; Wu X; Yang H
Sci Rep; 2015 Sep; 5():14035. PubMed ID: 26358014
[TBL] [Abstract][Full Text] [Related]
55. Analysis of PIK3CA mutations in breast cancer subtypes.
Arsenic R; Lehmann A; Budczies J; Koch I; Prinzler J; Kleine-Tebbe A; Schewe C; Loibl S; Dietel M; Denkert C
Appl Immunohistochem Mol Morphol; 2014 Jan; 22(1):50-6. PubMed ID: 24471188
[TBL] [Abstract][Full Text] [Related]
56. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
Oshiro C; Kagara N; Naoi Y; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2015 Apr; 150(2):299-307. PubMed ID: 25736040
[TBL] [Abstract][Full Text] [Related]
57. The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy.
Poetsch N; Sturdza A; Aust S; Polterauer S; Grimm C; Schwameis R; Pötter R; Koelbl H; Reinthaller A; Seebacher V
Strahlenther Onkol; 2019 May; 195(5):430-440. PubMed ID: 30737542
[TBL] [Abstract][Full Text] [Related]
58. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.
Hayes MP; Douglas W; Ellenson LH
Gynecol Oncol; 2009 Jun; 113(3):370-3. PubMed ID: 19272638
[TBL] [Abstract][Full Text] [Related]
59. PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis.
Fariña Sarasqueta A; Zeestraten EC; van Wezel T; van Lijnschoten G; van Eijk R; Dekker JW; Kuppen PJ; Goossens-Beumer IJ; Lemmens VE; van de Velde CJ; Rutten HJ; Morreau H; van den Brule AJ
Cell Oncol (Dordr); 2011 Dec; 34(6):523-31. PubMed ID: 21830111
[TBL] [Abstract][Full Text] [Related]
60. Clinicopathological and biological analysis of
Razia S; Nakayama K; Nakamura K; Ishibashi T; Ishikawa M; Minamoto T; Iida K; Otsuki Y; Nakayama S; Ishikawa N; Kyo S
Exp Ther Med; 2019 Sep; 18(3):2278-2284. PubMed ID: 31410178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
